Division of HIV and STD Programs, Los Angeles County Department of Public Health, Los Angeles, California.
J Med Virol. 2014 Oct;86(10):1639-47. doi: 10.1002/jmv.23989. Epub 2014 Jun 27.
The prevalence of transmitted HIV drug resistance (TDR) in Los Angeles County remains unknown, due in part to the absence of reliable genotypic data. The specific objectives of this study are to estimate the prevalence of TDR, to describe the demographic characteristics associated with TDR and to investigate the distribution of HIV-1 subtypes among persons newly diagnosed with HIV in Los Angeles County. From 2007 through 2009, 1,414 sequences were obtained from 7,100 persons newly diagnosed with HIV through HIV resistance surveillance. Overall, 257 (18%) sequences had some genetic evidence of drug resistance. Of these, 122 (9%) exhibited evidence of resistance to non-nucleoside reverse transcriptase inhibitors, 121 (9%) to nucleoside reverse transcriptase inhibitors and 76 (5%) to protease inhibitors. Subtype B was dominant (97%), followed by subtypes C (1.2%), CRF01_AE (0.8%), CRF02_AG (0.4%), A (0.3%), and F (0.1%). With a TDR prevalence of 18%, Los Angeles County ranks high compared with other jurisdictions across the nation. The prevalence of TDR in recent (19%) and long-standing (17%) HIV cases were similar, thus providing additional support for the notion that TDR-associated mutations may persist well beyond the period of recent infection. HIV-1 CRF01_AE, observed historically in central Africa and Asia, was observed to be circulating among men who have sex with men and heterosexuals in Los Angeles County. These findings underscore the need for continued and expanded HIV resistance surveillance to inform healthcare providers, policy makers and at-risk populations of emerging trends in HIV drug resistance.
洛杉矶县的传播性 HIV 耐药(TDR)流行率尚不清楚,部分原因是缺乏可靠的基因分型数据。本研究的具体目的是估计 TDR 的流行率,描述与 TDR 相关的人口统计学特征,并研究新诊断为 HIV 的人群中 HIV-1 亚型的分布。从 2007 年到 2009 年,通过 HIV 耐药监测从 7100 名新诊断为 HIV 的患者中获得了 1414 个序列。总体而言,257 个(18%)序列有一些药物耐药的遗传证据。其中,122 个(9%)显示出对非核苷类逆转录酶抑制剂的耐药证据,121 个(9%)对核苷类逆转录酶抑制剂,76 个(5%)对蛋白酶抑制剂。B 亚型占主导地位(97%),其次是 C 亚型(1.2%)、CRF01_AE(0.8%)、CRF02_AG(0.4%)、A 亚型(0.3%)和 F 亚型(0.1%)。TDR 流行率为 18%,与全美其他司法管辖区相比,洛杉矶县排名较高。近期(19%)和长期(17%)HIV 病例的 TDR 流行率相似,这进一步支持了 TDR 相关突变可能在近期感染期过后很长时间内持续存在的观点。HIV-1 CRF01_AE 历史上在中非和亚洲观察到,在洛杉矶县的男男性行为者和异性恋者中传播。这些发现强调需要继续和扩大 HIV 耐药监测,以便向医疗保健提供者、政策制定者和高危人群通报 HIV 耐药方面的新趋势。